New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
09:03 EDTKINKindred Biosciences announces initiation of pivotal clinical study for SentiKin
Kindred Biosciences announced that it has initiated the pivotal clinical trial for SentiKinfor post-operative pain in dogs. SentiKin is a centrally acting non-opioid, non-steroidal anti-inflammatory and non-steroidal analgesic drug. The proposed mechanism of action of SentiKin's active ingredient is selective potassium channel opening activity with NMDA receptor antagonist properties, with resultant anti-nociceptive, anti-seizure, muscle relaxant, and neuroprotective activities.
News For KIN From The Last 14 Days
Check below for free stories on KIN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
15:57 EDTKINKindred Biosciences 1.1M shares block trade priced at $10.50
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use